Drugs / STR-P004
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07003178 | Jun 2025 → Apr 2026 overdue | non-Hodgkin lymphoma | Starna Therapeutics | Not yet recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07363954 | Feb 2026 → Feb 2027 expected | autoimmune disease | Starna Therapeutics | Not yet recruiting | No outcome recorded |
| — | NCT07245251 | Dec 2025 → Nov 2026 expected | B-cell acute lymphoblastic leukemia | Starna Therapeutics | Not yet recruiting | No outcome recorded |
| — | NCT07143617 | Sep 2025 → Aug 2026 overdue | autoimmune disease | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STR-P004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07003178 ↗ |
| Route | Intravenous | “administered intravenously” NCT07003178 ↗ |